Intravitreal triamcinolone acetonide in the treatment of macular edema due to retinal vein occlusion
10.3969/j.issn.1672-5123.2010.06.002
- VernacularTitle:玻璃体腔注射曲安奈德治疗视网膜静脉阻塞黄斑水肿
- Author:
Meng-Xiang, GUO
;
Chang-Xian, YI
;
Dao-Man, XIANG
- Publication Type:Journal Article
- Keywords:
macular edema;
retinal vein occlusion;
triamcinolone acetonide
- From:
International Eye Science
2010;10(6):1030-1032
- CountryChina
- Language:Chinese
-
Abstract:
·AIM: To evaluate the efficacy and safety of intravitreal triamcinolone acetonide(TA) as treatment for macular edema associated with retinal vein occlusion(RVO).·METHODS: The study group consisting 30 patients (30 eyes) with RVO combined with macular edema received intravitreal 4mg TA. Changes in best-corrected visual acuity (BCVA), intraocular pressure(IOP), examination with slit-lamp microscope, fluorescein angiography and optical coherence tomography(OCT) were observed during the follow-up. Statistical analysis was conducted with SPSS 12.0 software.·RESULTS: The visual acuity(VA) of all patients was significantly improved and the central macular thickness (CMT) was significantly relieved. There was no correlation between course, age, CMT before injection and the type of RVO. There was positive correlation between visual acuity before injection and after injection.·CONCLUSION: Intravitreal injection of TA is an easy-operated and safe therapy. After injection, macular edema can be rapidly relieved. VA at baseline is the predictor for the prognosis of VA. Some patients experience recurrence of macular edema between 3 to 6 months after injection.
